Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2pos Breast Cancer
Although immune-based therapies have made remarkable inroads in cancer treatment, they usually must be combined with standard treatment modalities, including cytotoxic drugs, to achieve maximal clinical benefits. As immunotherapies are further advanced and refined, considerable efforts will be requi...
Saved in:
Main Authors: | Nirmala Ghimirey, Chase Steele, Brian J. Czerniecki, Gary K. Koski, Loral E. Showalter |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | International Journal of Breast Cancer |
Online Access: | http://dx.doi.org/10.1155/2021/8818393 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model
by: Ken S. Rosenthal, et al.
Published: (2017-01-01) -
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
by: Femke A. I. Ehlers, et al.
Published: (2025-01-01) -
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01) -
Role of Fcγ receptors in HER2-targeted breast cancer therapy
by: Hope S Rugo, et al.
Published: (2022-01-01) -
Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer
by: Solmaz AghaAmiri, et al.
Published: (2021-01-01)